Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Peel Hunt
$23.00
Provider: Peel Hunt
$23.00
Provider: Peel Hunt
$943.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Circassia Pharmaceuticals PLC announces results from Phase IIb Study


Friday, 13 Jun 2014 02:00am EDT 

Circassia Pharmaceuticals PLC:Says positive top-line results from a two-year follow-up of a phase IIb clinical study of HDM-SPIRE, a house dust mite allergy product candidate based on Circassia's ToleroMune platform technology. 

Latest Developments for Circassia Pharmaceuticals PLC